IVEVF News and Press, Inventiva SA From 03/28/24

Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysf...

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million 1 , and long-term deposit at €9.0 million 2 as of December 31, 2023, comp...

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatoh...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid meta...

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of me...

Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in sites operating under central IRB in the US. Other sites and count...

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million 2 , and long-term deposit at €9.0 million 3 as of December 31, 2023, compared to...

Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients wit...

Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH. This second tranche carries an interest rate of 7% annually and has a maturity of 3 years and a repayment in fine which is expected to occur...

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects to have met the operational and financial conditions precedent to draw the second €25...